Constellation Pharmaceuticals, Inc. announced to discuss the data from two oral presentations and two posters on the MANIFEST clinical trial for CPI-0610. The event will include: a review of the clinical and translational data from MANIFEST presented during ASH, including 24-week data from 50 – 60 first-line and 90 –100 second-line myelofibrosis patients, and a physician panel discussion and question-and-answer session with Dr. John Mascarenhas, Associate Professor of Medicine?at the Icahn School of Medicine at Mount Sinai- New York and Dr. Serge Verstovsek, Professor of Medicine at University of Texas MD Anderson Cancer Center. MANIFEST is an open-label Phase 2 clinical trial of CPI-0610 in patients with myelofibrosis (MF), a rare cancer of the bone marrow that disrupts the body’s normal production of blood cells. Constellation is evaluating CPI-0610 in combination with ruxolitinib in JAK-inhibitor-naïve MF patients (Arm 3), with a primary endpoint of the proportion of patients with a =35% spleen volume reduction from baseline (SVR35) after 24 weeks of treatment. Constellation is also evaluating CPI-0610, either as a monotherapy in patients who are resistant to, intolerant of, or ineligible for ruxolitinib and no longer on the drug (Arm 1), or as add-on therapy in combination with ruxolitinib in patients with a sub-optimal response to ruxolitinib or MF progression (Arm 2). Patients in Arms 1 and 2 are being stratified based on Transfusion Dependence (TD) status. The primary endpoint for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to Transfusion Independence for 12 consecutive weeks. The primary endpoint for the patients in cohorts 1B and 2B, who were not TD at baseline, is the proportion of patients with a =35% spleen volume reduction from baseline after 24 weeks of treatment.